AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
HONOLULU -- A prospective analysis of 10 years of pregnancy registry data has found no evidence that use of the anticonvulsant lamotrigine in the first trimester is associated with an increase in major birth defects, Dr. Mark S. Yerby reported.
Lamotrigine (Lamictal) is classified as Pregnancy Category C as a result of animal studies indicating teratogenic effects and is contraindicated in pregnancy But women with epilepsy often cannot easily be removed from lamotrigine when they become pregnant, he said at the annual meeting of the American Academy of Neurology.
He and his colleagues analyzed data from the GlaxoSmithKline International Lamotrigine Pregnancy Registry They included only women who were enrolled in the registry before the results of their pregnancies became known. The investigators used the Centers for Disease Control and Prevention definition of major birth defects.
Of the 248 qualifying pregnancies involving lamotrigine monotherapy in the registry as of September 2002, six infants had major birth defects. The risk of major birth defects was 2.4%. This compares favorably with general population ...